foxo4-dri senolytic peptide human trial 2024 2025 alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Peptide inhibitors targeting FOXO4-p53 interactions

Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Senescent cells as a target for anti aging interventions: From senolytics to immune therapies PMC The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications (PDF) Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes

SKU: 37108765334 · From webdevsolutions.tech